Osimertinib is a third‐generation irreversible, oral EGFR‐TKI that potently and selectively inhibits both EGFR‐TKI sensitizing and EGFR T790M resistance mutations that has demonstrated efficacy in NSCLC CNS metastasis.14, 15, 16, 17, 18, 19. Here, EGFR is linked to non-small cell lung carcinoma.